Kymera Therapeutics Presents KT-621 Clinical Data for Atopic Dermatitis

Bitget2026/10/29 13:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kymera Therapeutics completed enrollment in its KT-621 Phase 2b atopic dermatitis trial, with data expected by year-end 2026.
Phase 3 atopic dermatitis trials are planned to begin by mid-2027; the KT-621 program is six months ahead of schedule.
The ongoing KT-621 Phase 2b asthma trial is expected to report data in late 2027.
Earlier Phase 1b results showed a 63% mean EASI reduction, with no serious or severe adverse events.
KT-579, an oral IRF5 degrader, is scheduled to enter the LUMORA Phase 1b lupus trial by early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kymera Therapeutics Presents KT-621 Clinical Data for Atopic Dermatitis

You may also like

Crypto prices